Egypt's Mahmoud Mohiedin elected as IMF executive director, board member    UAE government delegation heads to Israel for first official visit    France's Macron, Iraq PM highlight importance of fight against terrorism    Eight positive in latest Premier League COVID-19 tests    PSG to focus on countering Manchester United counter attacks    Turkey's daily COVID-19 patients top 2,000, at early-May levels    Brexit in limbo: UK says there is no point talking until EU gets serious    What are the treatment options for COVID-19?    Saudi retail chains join growing informal boycott of Turkish products    South Africa's health minister gets COVID-19, as cases rise    Abu Dhabi's ADQ to invest $1 billion to help retailer Lulu expand in Egypt    Zamalek coach expects tough clash in Cairo despite Casablanca win    Guinea decides on third term for Conde amid voter-card concerns    Egypt faces major challenge in balancing between water resources and needs: Minister    Egypt's Senate members take constitutional oath    Book Review - On Lover's Conditions    Renowned Egyptian actor Mahmoud Yassin dies at 79    Harpist Manal Mohieddin gives a concert at the Cairo Opera House    Egyptian insurance companies' premiums 9.6% up in five months    Egypt's President Sisi names new head of anti-corruption watchdog    Egypt's c.bank offers 18 bln pounds T-bills on Sunday    EgyptAir offering discounts for some international flights    Egypt records 212 new coronavirus cases, 14 deaths on Saturday    Egypt to require PCR coronavirus tests for airport travelers    Egypt sends 125 tonnes of glass by sea to Beirut    Legend Messi officially wants to leave Barcelona, hands transfer request    Global smartphone sales drop 20% in Q2, yet Apple's iPhone sales steady    Sisi: Egypt keen on establishing development projects with Iraq, Jordan    Egyptian megastar Amr Diab releases new hit music video    Making of Harry Potter will be available for fans at new park in Tokyo    Egypt's Senate elections official results to be announced Wednesday    Netflix Egypt is bringing megastar Amr Diab back with a new original    Egypt reopens Rafah border crossing for first time since April    Egypt's senate elections 2020 trending on social media in few days    African Champions League final will be played on Oct. 16-17, CAF says    No room to delay Egyptian Premier League games – EFA's board member    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Britain secures 60 mln doses of Sanofi/GSK coronavirus vaccine
Published in Ahram Online on 29 - 07 - 2020

Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.
With its four deals so far, Britain has struck more coronavirus vaccine supply agreements than any other country, securing 250 million doses for a population of 66 million.
But with no vaccine yet proven to work, a range of potential suppliers is seen as giving the best chance of success.
"The fact remains that there are no guarantees," said business minister Alok Sharma.
"It is important that we secure early access to a diverse range of promising vaccine candidates ... to increase our chances of finding one that works."
Sanofi and GSK confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was positive.
It is Sanofi and GSK's first deal to supply their experimental coronavirus vaccine to a country.
Financial terms were not disclosed.
Asked about the price, GSK CEO Emma Walmsley said only that GSK did not expect to profit from the product during the pandemic and any short-term earnings would be partly be reinvested into pandemic preparedness and donated to developing countries.
With more than 20 vaccines in human trials, the move could stir concerns that rich countries, including the United States and those in Europe, are scooping doses in advance, potentially to the detriment of poorer nations.
Last week, Britain struck deals for 30 million doses of an experimental BioNtech/Pfizer vaccine, and a deal in principle for 60 million doses of Valneva's potential shot, which followed a previously announced deal for 100 million doses of an experimental Oxford/AstraZeneca vaccine.
The EU and United States have secured 400 million and 300 million doses of the Oxford/AstraZeneca shot respectively, while the U.S. government has also agreed to buy 100 million doses of the Pfizer/BioNtech vaccine, with an option for 500 million more.
The Sanofi/GSK vaccine combines Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology, and the first clinical trials are expected in September.
Adjuvants are efficacy boosters that play a vital role in many traditional vaccines. Sanofi and GSK's vaccine uses a different approach from either the Oxford/AstraZeneca or Pfizer/BioNtech vaccines.
Sanofi and GSK said talks to supply their vaccine to the EU, Italy and France were ongoing.
The two firms hope to clinch a deal soon to provide 300 million doses to the EU, though two sources told Reuters that negotiations had stalled.
Britain decided against joining the EU's vaccine purchase scheme in order to strike its own deals.


Clic here to read the story from its source.